Background-Mutations in thin-filament proteins have been linked to hypertrophic cardiomyopathy, but it has never been demonstrated that variants identified in the TNNC1 (gene encoding troponin C) can evoke cardiac remodeling in vivo. The goal of this study was to determine whether TNNC1 can be categorized as an hypertrophic cardiomyopathy susceptibility gene, such that a mouse model can recapitulate the clinical presentation of the proband. Methods and Results-The TNNC1-A8V proband diagnosed with severe obstructive hypertrophic cardiomyopathy at 34 years of age exhibited mild-to-moderate thickening in left and right ventricular walls, decreased left ventricular dimensions, left atrial enlargement, and hyperdynamic left ventricular systolic function. Genetically engineered knock-in (KI) mice containing the A8V mutation (heterozygote=KI-TnC-A8V
W hen intracellular Ca
2+ levels saturate cardiac troponin C's (cTnC) single low-affinity regulatory Ca 2+ -binding site II, a series of conformational changes occur among the proteins that make up the thin filament, allowing myosin to cycle faster with actin, thus leading to force generation. 1 Troponin C is part of a regulatory trimeric protein troponin complex (Tn) situated at regular intervals along the thin filament. Tn also comprises troponin I (TnI), which inhibits cross bridge formation between myosin and actin and troponin T, which is important for myofilament activation and anchoring of the Tn complex to the thin filament. 2, 3 Fluctuations in intracellular Ca 2+ during excitation-contraction coupling control the contractile and relaxation phases of cardiac contraction. 1 Hence, perturbations in the Ca 2+ affinity of cTnC can modify myofilament function, as demonstrated by in vitro studies. 4, 5 In an effort to determine whether the TNNC1 (cTnC gene) might be associated with hypertrophic cardiomyopathy (HCM), a large cohort of unrelated HCM patients was screened for mutations, which revealed the existence of 4 rare cTnC variants. 6 Recently, 2 other TNNC1 mutations have been identified in HCM patients. 7, 8 Direct evidence that points toward causality for these mutations is lacking. The absence of positive family history of HCM disease or comprehensive linkage analysis has hindered the designation of TNNC1 as an established HCM susceptibility gene. 6 Therefore, what has remained elusive is an established link between the variants found in TNNC1 and the disease processes that lead to the development of HCM.
Our laboratory has used in vitro tools to define cTnC variants as disease causing by assaying for functional changes and determining whether they fit within parameters of known, established pathogenic thin filament HCM mutations. 6, 9, 10 In this regard, a rare heterozygote variant A8V in TNNC1 was identified in an HCM patient who was genotype-negative for mutations in 8 other sarcomeric protein genes. 6 The substitution of alanine for valine at position 8 in cTnC is located in the N-helix, which is known to modulate Ca 2+ -binding affinity of both the C-and N-terminal domains. 11, 12 Assessments were made as to whether cTnC-A8V led to disease-like properties in functional tests that included porcine-skinned fibers and reconstituted actomyosin ATPase assays. 6, 9 In reconstituted functional assays, the cTnC-A8V mutant demonstrated an ability to sensitize the myofilament to Ca 2+ . 6, 9 Although this compilation of findings strongly suggested that the cTnC-A8V mutant was the cause of HCM in the patient, additional proof was still necessary. The proband had a negative family history of HCM, and therefore, the rare variant could not be shown to segregate with the disease.
Here, we describe the functional consequences of the first cTnC animal model generated to date, a mouse bearing the mutation A8V inserted via a knock-in strategy. As in the TNNC1-A8V proband, the knock-in (KI) mouse containing the cTnC-A8V (KI-TnC-A8V) also developed mild to moderate left-and right ventricular hypertrophy, hyperdynamic systolic function, and atrial enlargement. Furthermore, we explored the underlying cellular and molecular mechanisms governing the disease process in the KI-TnC-A8V mice. Altered mechanical function and Ca 2+ handling in intact cardiomyocytes were accompanied by increased Ca 2+ sensitivity of contraction, likely contributing to cardiac dysfunction. Profound clinical similarities regarding the manifestation of disease in the patient and animal model provide evidence that increased cTnC N-domain Ca 2+ affinity is an underlying mechanism of HCM and that TNNC1-A8V is a definite HCMcausative mutation. Altogether, these findings further establish that TNNC1 is a HCM susceptibility gene.
Methods
For further details, see Methods in Data Supplement.
Clinical Data
The proband was presented to Mayo Clinic for clinical evaluation and management of HCM and consented to participate in an IRBapproved protocol. 6 
Mice
All protocols and experimental procedures followed National Institutes of Health guidelines and were approved by University of Miami, Florida State University, and Wayne State University Animal Care and Use Committee.
Statistical Analysis
All values are presented as mean±SE Significance for echocardiography (ECHO), gene expression levels, Ca 2+ and contractile transients in intact cardiomyocytes, Ca 2+ sensitivity of contraction and flash photolysis in skinned fibers, and immunoblot data were determined by 1-way ANOVA using Fisher least significant difference or Bonferroni post hoc analysis. Significance for body weight (BW), heart weight (HW)/ BW, atrial weight, and atrial/HW were determined by 1-way ANOVA with Tukey post hoc analysis, whereas 2-way or 1-way ANOVA with Tukey post hoc analysis was used for pressure-volume (P-V) studies depending on the comparison indicated in the legend of Figure 2 . A priori alpha level of P<0.05 was considered to be significant.
Results

Clinical Presentation of the Patient With the TNNC1-A8V Mutation
The proband was first examined at the Mayo Clinic in 2003 and, after consenting to a study, was found to be genotype-positive for the rare missense A8V variant in TNNC1. Clinically, he was diagnosed with severe obstructive HCM at age 34, exhibiting increased left and right ventricular wall thickness and a left ventricular outflow tract gradient of 117 mm Hg at rest with systolic anterior motion of the mitral valve. An ECHO ( Figure 1A and 1B) was performed indicating (1) 
Echocardiography of KI-TnC-A8V Mice
The KI mice were analyzed by ECHO to determine how the cTnC-A8V variant affected cardiac function in mice at 3, 9, and 14 months of age. A representative M-mode image of the left ventricle from a 14-month-old KI-TnC-A8V +/+ mouse heart is shown in Figure 2B , in which a narrowing of the cardiac chamber lumen can be observed compared with age-matched wild-type (WT; Figure 2A ). The end-diastolic volume (μL), end-systolic volume, and left ventricular dimensions were reduced significantly in KI-TnC-A8V
+/+ at all ages tested. Left ventricular dimensions were significantly reduced only at 14 month for KI-TnC-A8V +/− compared with WT mice (see Table) . Because KI mouse hearts may undergo changes in size, we attempted to calculate relative wall thickness. As shown in Table, significant changes in relative wall thickness can be observed in KI-TnC-A8V +/− and KI-TnC-A8V +/+ hearts as early as 3 months compared with WT hearts. The EF was increased in KI-TnC-A8V +/+ mice at 3 and 9 months of age, suggesting hyperdynamic left ventricular systolic function that was also seen in the patient (Table) . The isovolumic contraction time was found decreased for the KI-TnC-A8V +/+ mice at 9 and 14 months of age. Additional changes occurred in parameters related to diastolic function (increased isovolumic relaxation time (RT) and decreased mitral valve early peak flow velocity/atrial peak flow velocity) for KI-TnC-A8V
+/+ at different ages, consistent with Stage I diastolic dysfunction. Clinical findings from the patient indicated a mitral valve early peak flow velocity/atrial peak flow velocity ratio of 1.13 (normal values 0.9-2.5) in an ECHO performed in 2003.
Pressure-Volume (P-V) Studies of KI-TnC-A8V Mice
Cardiac function was examined in ex vivo working heart preparations at baseline and 3, 10, or 30 nmol/L isoproterenol in 12-to 13-month-old mice. Higher stroke volumes were seen when normalized to HW in KI-TnC-A8V +/+ and KI-TnC-A8V +/− compared with WT hearts ( Figure 2C ), indicating augmented systolic function. KI-TnC-A8V +/− hearts had higher LVP max values compared with WT and KI-TnC-A8V +/+ hearts ( Figure 2D hearts were similar to that of WT hearts ( Figure 2F ).
Heart Weight of KI-TnC-A8V Mice
In 12-to 13-month-old mice, no significant difference was found in the BW of KI-TnC-A8V +/− and KI-TnC-A8V +/+ compared with WT mice ( Figure 3A) . However, the HW to BW ratio (HW/BW) was significantly reduced in both KI-TnC-A8V +/− and KI-TnC-A8V +/+ mice ( Figure 3B ). LA mass in KITnC-A8V +/+ mice was dramatically increased as shown by the increased weight of the LA alone and when compared with the whole heart weight LA/HW ratio compared with that of WT hearts ( Figure 3C and 3D), suggesting that adaptive remodeling occurred in response to impaired left ventricular diastolic function. No significant changes were observed in the right atria of these mice (data not shown).
Cardiac Fetal Gene Expression in Mutant KI-TnC-A8V Mice
Consistent with the previous findings indicating occurrence of a cardiomyopathic process, mRNA expression levels of brain natriuretic peptide and atrial natriuretic peptide by quantitative reverse transcriptase polymerase chain reaction were significantly increased in the left ventricle of 16-to 18-month-old KI-TnC-A8V +/+ and KI-TnC-A8V +/− mice compared with agematched controls, whereas mRNA expression levels of myosin heavy chain β increased only in the KI-TnC-A8V +/+ left ventricle ( Figure 3E ). In addition, we assessed the expression levels of fetal genes in the right ventricle. Only KI-TnC-A8V +/+ mice showed a significant increase in brain natriuretic peptide and atrial natriuretic peptide gene expression compared with WT mice ( Figure 3F ).
Assessment of Histopathology in KI-TnC-A8V Hearts
The hearts of 16-to 18-month-old mice were stained using Masson trichome and evaluated for changes in tissue 
Determination of Mutant to WT Protein Ratio in the KI-TnC-A8V +/− Hearts
Because we are studying KI mice with either 1 or 2 alleles mutated, we attempted to determine the ratio of mutant to WT cTnC protein incorporated into the KI-TnC-A8V +/− hearts. Heart extract samples of 4-month-old mice were resolved by 15% SDS-PAGE, and the cTnC band was excised and extracted from the SDS-PAGE gel, followed by trypsinization. The samples were then analyzed by liquid chromatography mass spectrometry quantification (see Methods in the Data Supplement for further details). Cardiac TnC was digested at the carboxy-termini of lysine 6 and 17 or 21. Both peptides one of 11 amino acids and the other of 15 amino acids contain the residue number 8 of cTnC. Figure 4G shows the retention time for the different peptides generated by cTnC trypsinization of the WT, KI-TnC-A8V +/− , and KI-TnC-A8V +/+ heart samples. The graphs show that the ratio quantified by the 2 peptides yielded the same result, 21.05±1.45% (15 amino acid peptide) and 21.45±1.15% (11 amino acid peptide) of the cTnC-A8V incorporated in the KI-TnC-A8V +/− hearts.
Sarcomere Length and Intracellular Ca 2+ Levels in Intact Cardiomyocytes From KI-TnC-A8V Mice
Intact cardiomyocytes were isolated from 3-month-old WT, KI-TnC-A8V +/− , and KI-TnC-A8V +/+ mouse hearts, and the intracellular Ca 2+ and sarcomere length (SL) parameters were recorded at 4 different stimulation frequencies (1, 2, 4, and 6 Hz). From these experiments, we sought to understand how hemodynamics was changed and whether function was impaired at the cellular level because of the incorporation of mutant cTnC into the myofilament. Figure 5A shows that diastolic SL was significantly shorter in KI-TnC-A8V +/− and KI-TnC-A8V +/+ cardiomyocytes compared with those of WT at all stimulation frequencies. Next, we evaluated the contractility percentage and found that the cTnC-A8V mutation present in both KI-TnC-A8V +/− and KI-TnC-A8V +/+ cardiac myocytes contributed to an increased contractile percentage at all frequencies of stimulation ( Figure 5B ). This finding is consistent with the hypercontractile phenotype as evidenced by the increased stroke volumes for KI-TnC-A8V +/− and KI-TnC-A8V +/+ and EF for KI-TnC-A8V +/+ reported in Figure 2C and Table. Further measurements were conducted to determine resting intracellular Ca 2+ levels, as monitored by Fura-2 pentakis (acetoxymethyl) ester. It was found that KI-TnC-A8V +/− cardiomyocytes possess higher diastolic Ca 2+ levels at all pacing frequencies compared with agematched WT cardiomyocytes, whereas KI-TnC-A8V +/+ showed lower diastolic Ca 2+ levels only at 6 Hz ( Figure 5C ). Furthermore, the peak Ca 2+ to baseline measured as a percentage was significantly diminished in both KI-TnC-A8V +/− and KI-TnC-A8V +/+ cardiomyocytes compared with WT cardiomyocytes, as shown in Figure 5D . The gene-dosage effect, however, is evident in the diastolic SL and peak Ca 2+ measurements. To further understand the cellular mechanisms underlying development of HCM elicited by introduction of the cTnC-A8V mutant in mice, we evaluated the kinetics of SL shortening and intracellular Ca 2+ transients in isolated cardiomyocytes (the representative raw and normalized data traces are shown in Figure IIIA in the Data Supplement). This experiment allowed us to investigate the effects of the mutant in an intact cellular system, without the complications of autonomic modulation. The experiment was conducted and recorded using a range of frequencies, from 1 to 6 Hz. In Figure 6A and 6B, the SL shortening and intracellular Ca 2+ kinetics parameters were recorded using 2 higher pacing frequencies (4 and 6 Hz) to evoke outcomes more consistent with cardiac mouse physiology. As shown in Figure 6A (top panels), the T 50 RT is determined to be 50% of the time it takes for the SL to return from peak to baseline, and was prolonged in KI-TnC-A8V +/− and KI-TnC-A8V +/+ cardiomyocytes at 4 and 6 Hz stimulation frequencies compared with WT cardiomyocytes. Note that at 4 Hz, the T 50 RT for SL in KI-TnC-A8V +/+ cardiomyocytes was also significantly prolonged compared with that in KI-TnC-A8V +/− cardiomyocytes. These results suggest that the kinetics of cardiomyocyte relaxation was affected in a gene dose-dependent fashion. The rates of cell relengthening at 4 and 6 Hz were consistent with results obtained for T 50 RT, excluding the possibility that a delay in SL relaxation could be caused by excessive cell shortening ( Figure 6A, middle panels) . The SL shortening time from baseline to peak was found to be significantly prolonged in KI-TnC-A8V +/+ and KI-TnC-A8V +/− cardiomyocytes at 4 and 6 Hz compared with WT cardiomyocyte. Note that KITnC-A8V +/+ cardiomyocytes was also significantly prolonged compared with KI-TnC-A8V +/− at both frequencies ( Figure 6A , bottom panels). Next, we investigated whether the slower SL shortening and relengthening kinetics found in KI-TnC-A8V cardiomyocytes correlated with changes in the Ca 2+ transient. The T 50 for Ca 2+ decay (50% of the time for the intracellular Ca 2+ to return from peak to baseline) was found to be significantly delayed in KI-TnC-A8V +/− and KI-TnC-A8V +/+ cardiomyocytes at both frequencies of stimulation compared with WT cardiomyocyte ( Figure 6B , top panels). The T 50 Ca 2+ decay was affected in a gene dosage fashion because it was found to be significantly different between cardiomyocytes obtained from KI-TnC-A8V +/− and KI-TnC-A8V +/+ . The time from baseline to peak for intracellular Ca 2+ was also investigated and found to be delayed in KI-TnC-A8V +/+ cardiomyocytes compared with KI-TnC-A8V +/− and WT cardiomyocytes when paced at 4 and 6 Hz ( Figure 6B, bottom panels) . The SL T 50 RT was found to be prolonged similarly in both KI-TnC-A8V +/− and KI-TnC-A8V +/+ cardiomyocytes when stimulated at lower frequencies compared with WT cardiomyocyte, whereas the effect of gene dosage on the delay in T 50 of Ca 2+ decay was also seen at 1 Hz ( Figure IIIB in the Data Supplement).
Ca
2+ Sensitivity of Contraction and Rate of Relaxation in Skinned Fibers From KI-TnC-A8V
To evaluate whether the TnC-A8V mutant elicited cellular, morphological, and hemodynamic changes in the heart Figure 7A . The cooperativity of thin filament activation (n Hill ) was significantly decreased in the KI-TnC-A8V +/+ (n Hill =1.79±0.06) skinned fibers compared with that from WT (n Hill =2.59±0.14) and KI-TnC-A8V +/− (n Hill =2.26±0.14), whereas the n Hill of the KI-TnC-A8V +/− skinned fibers remained unchanged compared with that of WT ( Figure 7A ). The same trend of increased Ca 2+ sensitivity appeared to occur in a gene-dose-dependent fashion when the experiments were conducted with 14-to 16-month-old mice. The n Hill from the 14-to 16-month-old mice also followed the same trend as that of the 4-month-old group ( Figure IV in the Data Supplement). Flash photolysis of the diazo-2-loaded skinned fibers indicated that the rate of relaxation was significantly slower for KI-TnC-A8V +/+ compared with WT (Figure 7B) . The rate constants and amplitudes are included in the figure legend.
Immunoblotting for Detection of Key Ca
2+ -Handling Proteins in KI-TnC-A8V Hearts
The proteins responsible for loading the sarcoplasmic reticulum (SR) were assessed to determine whether they underwent adjustments to maintain cellular Ca 2+ homeostasis. Figure 7C shows the representative immunoblots for 9-month-old hearts. The rationale for conducting these experiments at this age is to identify early molecular markers for the disease in KITnC-A8V +/− mice because morphological changes are still not evident. Sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2) protein levels were reduced in heart extracts obtained from KI-TnC-A8V +/− and KI-TnC-A8V +/+ mice ( Figure 7D ). The phosphorylation levels of serines 23, 24 in cTnI (TnI-P) were also reduced in both KI-TnC-A8V compared with WT hearts, whereas the phosphorylation levels of serine 16 in PLN (PLN-P Ser16 ) were significantly decreased only in KI-TnC-A8V +/+ hearts ( Figure 7D ). The protein levels of phospholamban (PLN-T), calsequestrin (CASQ2), and Na + Ca
2+
-exchanger (NCX1) were found unaltered in KI-TnC-A8V +/− and KITnC-A8V +/+ heart extracts ( Figure 7D ). We also looked for changes that occurred in protein expression and phosphorylation of SERCA2 and PLN, respectively, in younger (4-monthold) and older (16-to 18-month-old) groups of mice ( Figure  V in the Data Supplement). Interestingly, the phosphorylation levels of threonine 17 in PLN (PLN-P Thr17 ) were statistically lower in both KI-TnC-A8V +/− and KI-TnC-A8V +/+ hearts throughout the 3 ages tested. The levels of PLN-P Ser16 in KITnC-A8V +/− hearts were reduced at 4 months, unchanged at 9 months, and again reduced at 16 to 18 months compared with WT hearts, suggesting that some adaptation process to disease has occurred by midage. In KI-TnC-A8V +/+ hearts, the levels of PLN-P Ser16 were lower at all the different ages tested. The levels of PLN-T were lower in both KI-TnC-A8V genotypes Table I in the Data Supplement.
only at 16 to 18 months, whereas SERCA2 was lower at 9 months and 16 to 18 months ( Figure V in the Data Supplement). These data suggest that decreased levels of SERCA2 and PLN-P Thr17 could provide early molecular indicators of disease in KI-TnC-A8V +/− hearts.
Discussion
The objectives of this work were (1) to provide conclusive evidence that TNNC1 is an uncommon but definitive HCM-susceptibility gene; (2) to determine whether changes in the N-terminal domain Ca
2+
-binding affinity of cTnC in a KI mouse containing A B Figure 6 . Kinetics of contractility and Ca 2+ transients in KI-TnC-A8V intact cardiomyocytes electrically stimulated at 4 and 6 Hz. A, Time for the sarcomere length (SL) to return to 50% of baseline (RT, relaxation time); the rate of cell relengthening (−dL/dt); and time for SL shortening to achieve the peak value. B, Time for intracellular Ca 2+ to return to 50% of baseline and the time for intracellular Ca 2+ to achieve peak during systole. Data are shown as mean±SE, n=3 to 4 mice. the human HCM-associated A8V mutation are sufficient to induce cardiac remodeling that resembles cardiomyopathic human diseases; and (3) to investigate the cellular and molecular mechanism underlying the morphological changes in the heart and diastolic dysfunction caused by the aforementioned mutation, while correlating all these results with the clinical phenotytpe of the proband. On initial evaluation, the proband reported a negative family history of HCM because his children had not developed disease at this point. Therefore, the lack of unambiguous linkage studies for the cTnC variants discovered has thus far prevented the firm establishment of TNNC1 as an HCM-susceptibility gene. To date, there are 7 cTnC mutations described that are associated with HCM, and only 2 have demonstrated inheritance among family members. [6] [7] [8] 13 Because of the lack of co-segregation studies, in vivo studies, such as the one presented here, are therefore of utmost importance. Here we report the cardiac phenotype obtained in the first mouse model specifically designed to test the role of TNNC1 in HCM-associated disease processes.
Similar to the KI-TnC-A8V mouse model presented here, animal models bearing troponin T or TnI mutations associated with HCM either had unchanged or decreased HW/BW ratio. [14] [15] [16] [17] Although mouse models do not entirely recapitulate human disease processes, some disease traits are still manifested, for example, diastolic dysfunction and predisposition to arrhythmias. 14, 18, 19 In this study, we attempted to correlate morphological changes in the heart of the human patient with those of the mouse model containing the TNNC1-A8V mutation. The KI-TnC-A8V mouse mirrored the cardiac remodeling seen in the patient, who displayed mild to moderate right and left ventricular hypertrophy and LA enlargement as shown by relative wall thickness and histopathologic studies. Furthermore, the KI mouse developed mild diastolic dysfunction and hyperdynamic left ventricular function similar to what was observed in the patient (EF=73%). The data obtained from the TNNC1-A8V mouse model strongly suggest that this variant is indeed a definitive, pathogenic mutation.
Diastolic dysfunction is a clinical hallmark of HCM. Therefore, an important question to address is the source of impaired left ventricular relaxation. On studying the KI-TnC-A8V mouse, we identified interstitial fibrosis and myofibrillar disarray. These changes in tissue organization may contribute to increased stiffness and impaired muscle relaxation in HCM patients. 20 The LA enlargement seen in the TNNC1-A8V patient and in the KI mouse suggest that this mutation may also be implicated in the development of an restrictive cardiomyopathy (RCM)-like phenotype. This mixed phenotype has become acknowledged in the contemporary classification of inherited cardiomyopathy, which highlights the clinical overlap in the presentation of cardiomyopathies, such as HCM and RCM, defined previously as distinct clinical entities. 21 Experiments performed at the cellular level with KI-TnC-A8V cardiomyocytes indicated a delay in mechanical relaxation and intracellular Ca 2+ decay times. The molecular explanation for this phenomenon may be that the A8V substitution increases the Ca 2+ -binding affinity of cTnC and consequently delays the Ca 2+ dissociation rate from the thin filament, which we have previously shown in reconstituted systems. 22, 23 The drastic Ca 2+ sensitization observed in reconstituted porcine cardiac fibers (+0.36 pCa units) supported our rationale to subsequently develop the KI-TnC-A8V mouse because this cTnC mutant elicited the largest shift in this parameter among the other cTnC HCM mutants tested. 6 Measurements of the Ca 2+ sensitivity of contraction in the KI-TnC-A8V skinned fibers recapitulated our previous findings in reconstituted fibers. These data suggest that increased myofilament Ca 2+ sensitization causes the impaired mechanical relaxation and delayed Ca 2+ reuptake times in the intact KI-TnC-A8V cardiomyocytes, thus fitting a common pathogenetic process seen in TnI and troponin T models of HCM. 14, 16, 24 More recently, we and others have shown that genetically engineering the myofilament to desensitize it to Ca 2+ can potentially reverse the aberrant phenotypes associated with HCM and RCM caused by troponin and tropomyosin mutations. 25, 26 We found that KI-TnC-A8V cardiomyocytes have shortened SLs during diastole and reduced intracellular Ca 2+ oscilation between diastole and systole. These findings led us to hypothesize that under resting conditions, the cardiac myofilaments containing cTnC-A8V are preactivated. 24, 27 Thus, only a small increase in intracellular Ca 2+ levels (lower than normal physiological requirements) is sufficient to trigger muscle activation equivalent to or greater than that occurring during systole because EF and SL percentage of contraction in cardiomyocytes was increased. We and others have reported that HCM and RCM troponin mouse models may have a basal activation of contraction under resting conditions in skinned fibers and intact cells. This, in turn, impairs the relaxation phase in diastole. 14, 16, 28 Adjustments to the levels of Ca 2+ -handling proteins at the plasma membrane and the SR are known to occur during heart disease. Consistent with other mouse models of HCM, levels of SERCA2 were found to be decreased in the KI-TnC-A8V hearts, suggesting that the SR is unable to properly buffer intracellular Ca 2+ levels. Therapeutics that increase Ca 2+ buffering in cardiomyocytes during active disease states, such as HCM and RCM, have been successfully tested in mouse models. 29, 30 Interestingly, in our study, the levels of PLN-P Thr17 were found to decrease in KI-TnC-A8V hearts from 4 months of age onwards, whereas the levels of PLN-P Ser16 fluctuated in KI-TnC-A8V +/− mouse hearts at the 3 ages tested. This suggests that alterations in Ca 2+ handling because of the mutant cTnC protein may be sensed at a young age and that compensatory measures are well in place by 9 month of age, which further assist in regulation of Ca 2+ homeostasis. However, on further aging, the stress induced by the mutant cTnC protein seems to overwhelm the regulatory compensation, and the SR proteins are once again relied on as the main assistive mechanism regulating contractile function, whereas bimodal regulation by PLN-P may fine-tune SR Ca 2+ uptake during progression of disease. Changes in phosphorylation of PLN, cTnI, and SERCA2 protein levels occur even before visible structural changes are detected in the KI-TnC-A8V +/− heart. The decreased levels of PLN-T seen only at 16 to 18 months may indicate that the disease may have progressed to a more advanced stage and a combination of disease and effects of aging. The decreased levels of cTnI-P observed in KI-TnC-A8V mouse hearts is suggested to be a hallmark of the disease process because it was previously found that cardiac samples obtained from HCM patients who harbor mutations in sarcomeric proteins have decreased levels of cTnI-P. 31 The decreased phosphorylation levels of cTnI may be explained by the increased activity of phosphatases seen in patients transitioning into different stages of disease, such as heart failure. 32 Herein, we describe the functional consequences of the first cTnC animal model generated to date, a mouse that bears the human heterozygous mutation A8V inserted via a knockin strategy. The heterozygote and homozygote mice displayed functional and morphological changes that were consistent overall with the HCM phenotype, presenting a striking correlation to the phenotype of the human proband. In conclusion, this study provides compelling evidence that mutation in TNNC1 is a pathogenic mechanism that underlies the development of HCM.
